Alder Biopharmaceuticals, Inc.
(NASDAQ : ALDR)

( )
ALDR PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.99%285.431.4%$838.91m
CELGCelgene Corp.
-1.09%108.131.3%$697.32m
AMGNAmgen, Inc.
1.74%224.501.3%$537.91m
GILDGilead Sciences, Inc.
1.10%65.001.0%$396.48m
VRTXVertex Pharmaceuticals, Inc.
2.38%215.001.9%$331.77m
ILMNIllumina, Inc.
1.42%311.013.5%$325.81m
REGNRegeneron Pharmaceuticals, Inc.
1.26%344.462.6%$271.28m
EXASEXACT Sciences Corp.
2.00%83.8024.0%$220.87m
ALXNAlexion Pharmaceuticals, Inc.
2.48%110.652.0%$184.62m
SGENSeattle Genetics, Inc.
1.86%117.886.1%$144.97m
BMRNBioMarin Pharmaceutical, Inc.
3.41%77.734.3%$132.55m
SRPTSarepta Therapeutics, Inc.
0.14%98.0414.6%$118.36m
AAgilent Technologies, Inc.
1.80%79.341.6%$101.34m
BGNEBeiGene Ltd.
4.03%203.902.1%$93.79m
NBIXNeurocrine Biosciences, Inc.
-1.67%112.735.0%$87.98m

Company Profile

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.